Last reviewed · How we verify

Ontak — Competitive Intelligence Brief

Ontak (Ontak) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

marketed Interleukin-2 receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Ontak (Ontak) — The University of Texas Health Science Center at San Antonio.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ontak TARGET Ontak The University of Texas Health Science Center at San Antonio marketed Interleukin-2 receptor
Ontak DENILEUKIN DIFTITOX Eisai marketed CD25-directed Cytotoxin [EPC] Interleukin-2 receptor 1999-01-01
Ontak E7777 Eisai marketed CD25-directed Cytotoxin Interleukin-2 receptor 1999-01-01
Chrft5 BASILIXIMAB Novartis marketed Interleukin-2 Receptor Blocking Antibody [EPC] Interleukin-2 receptor subunit alpha 1998-01-01
Zenapax DACLIZUMAB Hoffman-La Roche marketed Interleukin-2 Receptor Blocking Antibody Interleukin-2 receptor 1997-01-01
Proleukin ALDESLEUKIN Chiron marketed Lymphocyte Growth Factor [EPC] Interleukin-2 receptor 1992-01-01
Simulect Simulect Astellas Pharma Inc marketed Interleukin-2 receptor subunit alpha

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ontak — Competitive Intelligence Brief. https://druglandscape.com/ci/ontak. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: